This webpage is intended for healthcare professionals within the European Union.04 November 2015
VARGATEF®: A triple angiokinase inhibitor approved in combination with docetaxel for the treatment of patients with distinct types of adenocarcinoma of the lung after first-line chemotherapy.1
Nintedanib is a triple angiokinase inhibitor blocking vascular endothelial growth factor receptors (VEGFR 1-3), platelet-derived growth factor receptors (PDGFR α and ß) and fibroblast growth factor receptors (FGFR 1-3) kinase activity1
In the LUME-Lung 1 trial, VARGATEF®, in combination with docetaxel, reached its primary endpoint by significantly prolonging progression-free survival in the ITT population compared with placebo plus docetaxel (3.4 months vs. 2.7 months, respectively; hazards ratio: 0.79 [95% CI 0.68-0.92]; P=0.0019). For the key secondary endpoint of the trial, VARGATEF®, when added to docetaxel, demonstrated over one year (12.6 months) median overall survival after first-line chemotherapy for advanced lung cancer patients in the subgroup with adenocarcinoma histology (vs. 10.3 months for patients receiving docetaxel plus placebo; hazards ratio: 0.83 [95% CI 0.70-0.99]; P=0.0359)1,2
The approval of VARGATEF® in the EU1 is primarily based on the results of the pivotal phase III trial LUME-Lung 1, which included over 1,300 patients in 27 countries2
To learn more about VARGATEF®, including dosing and patient management information, key results from the pivotal LUME-Lung 1 trial, or details of its mode of action (MoA), simply click on the sections headers above.
In the European Union, VARGATEF® is indicated for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma histology after first-line chemotherapy. For the EU Summary of Product Characteristics (SmPC) please click here. For country-specific information please click here.